Science Explorer Interactive view Map
Company · Preston · Australia

Novartis (Australia)

novartis.com.auROR OpenAlex
Research works
55
▼ 11% vs 2013–17
Citations
1.3k
23.0 per fractional work
Top-10% rate
1.3%
record average 16.5%
Open access
35%
world 28%

Not ranked overall: Novartis (Australia) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.51× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.11× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 8.00× its world share, 0 worksImmunology and Micro…Neuroscience: 2.17× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 3.75× its world share, 0 worksPharmacology, Toxico…Medicine: 3.77× its world share, 5 worksMedicineEconomics, Econometrics and Finance: 2.90× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 8.0×. Every wedge is a field page.

Which keywords describe research at Novartis (Australia)?

By fractional works in all years, weighted toward what it does more of than the world: Prognostic Factors, Rituximab, Mutation, BCR-ABL, Imatinib, Global Burden, Cardiovascular Disease and Clinical Guidelines.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Epidemiology6▲ 2.7×23 topics
  2. Prognostic Factors5▲ 20×5 topics
  3. Mutation4▲ 51×2 topics
  4. Rituximab4▲ 50×2 topics
  5. BCR-ABL4▲ 279×1 topic
  6. Imatinib4▲ 279×1 topic
  7. Cardiovascular Disease4▲ 6.7×7 topics
  8. Global Burden4▲ 13×2 topics
  9. Clinical Guidelines4▲ 22×3 topics
  10. Hypertension4▲ 19×3 topics
  11. Risk Factors4▲ 6.3×2 topics
  12. Antihypertensive Drugs3▲ 112×1 topic
  13. Blood Pressure3▲ 88×1 topic
  14. Cardiovascular Events3▲ 38×2 topics
  15. Chronic Lymphocytic Leukemia3▲ 128×1 topic
  16. Genomic Aberrations3▲ 128×1 topic
  17. Genetics3▲ 6.8×5 topics
  18. Classification3▲ 14×2 topics
  19. Quality of Life3▲ 3.6×7 topics
  20. Drug Resistance3▲ 15×3 topics
  21. Minimal Residual Disease2▲ 63×2 topics
  22. Diagnosis2▲ 3.9×11 topics
  23. Ivermectin2▲ 103×2 topics
  24. Livestock2▲ 55×2 topics
  25. Nematodes2▲ 63×2 topics
  26. Anthelmintic Resistance2▲ 155×1 topic
  27. Immune Response2▲ 5.8×7 topics
  28. Veterinary Parasites2▲ 155×1 topic
  29. Fusion Genes2▲ 118×1 topic
  30. Hypereosinophilic Syndrome2▲ 118×1 topic
  31. Lymphoma2▲ 18×3 topics
  32. Cost-effectiveness Analysis1▲ 33×1 topic
  33. Health Utility Measures1▲ 33×1 topic
  34. Acute Lymphoblastic Leukemia1▲ 64×1 topic
  35. Childhood Cancer1▲ 64×1 topic
  36. Chronic Disease Management1▲ 17×3 topics
  37. Vaccine Development1▲ 7.8×3 topics
  38. Diagnostic Criteria1▲ 11×3 topics
  39. Ecosystem1▲ 16×1 topic
  40. Parasites1▲ 55×1 topic

Which research topics does Novartis (Australia) publish most on?

By volume in 2022–2025: Multiple Sclerosis Research Studies, Lipoproteins and Cardiovascular Health, Chronic Myeloid Leukemia Treatments and Chronic Lymphocytic Leukemia Research.

Multiple Sclerosis Resea…1Multiple Sclerosis Research Studies: 1 fractional worksLipoproteins and Cardiov…0Lipoproteins and Cardiovascular Health: 0 fractional worksChronic Myeloid Leukemia…0Chronic Myeloid Leukemia Treatments: 0 fractional worksChronic Lymphocytic Leuk…0Chronic Lymphocytic Leukemia Research: 0 fractional worksLymphoma Diagnosis and T…0Lymphoma Diagnosis and Treatment: 0 fractional worksHealth Systems, Economic…0Health Systems, Economic Evaluations, Quality of Life: 0 fractional worksAortic Thrombus and Embolism: 0 fractional worksAcute Lymphoblastic Leukemia research: 0 fractional worksCAR-T cell therapy research: 0 fractional worksAcute Myocardial Infarction Research: 0 fractional works
Pathology and Forensic MedicineSurgeryHematologyGenetics5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Multiple Sclerosis Research Studies Pathology and Forensic Medicine 1 works
  2. 2 Lipoproteins and Cardiovascular Health Surgery 0 works
  3. 3 Chronic Myeloid Leukemia Treatments Hematology 0 works
  4. 4 Chronic Lymphocytic Leukemia Research Genetics 0 works
  5. 5 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  6. 6 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  7. 7 Aortic Thrombus and Embolism Pulmonary and Respiratory Medicine 0 works
  8. 8 Acute Lymphoblastic Leukemia research Public Health, Environmental and Occupational Health 0 works
  9. 9 CAR-T cell therapy research Oncology 0 works
  10. 10 Acute Myocardial Infarction Research Cardiology and Cardiovascular Medicine 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available35.1%not open64.9%

World: 28% of research is openly available.

with international co-authors34.9%domestic only65.1%

World: 19% is written across borders.

How has Novartis (Australia)'s research output changed?

Output in 2018–2022 was 11% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.